**References**

1.National Kidney Foundation.  K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease. * Am J Kidney Dis* 2003; **41**: S1--92.2.National Kidney Foundation.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. * Am J Kidney Dis* 2007; **49**: S1--180.3.Kasiske BL.  Hyperlipidemia in patients with chronic renal disease. * Am J Kidney Dis* 1998; **32**: S142--156.4.Bachorik PS, Ross JW.  National Cholesterol Education Program recommendations for measurement of low-density lipoprotein cholesterol: executive summary.  The National Cholesterol Education Program Working Group on Lipoprotein Measurement. * Clin Chem* 1995; **41**: 1414--1420.5.Stein EA, Myers GL.  National Cholesterol Education Program recommendations for triglyceride measurement: executive summary.  The National Cholesterol Education Program Working Group on Lipoprotein Measurement. * Clin Chem* 1995; **41**: 1421--1426.6.Warnick GR, Wood PD.  National Cholesterol Education Program recommendations for measurement of high-density lipoprotein cholesterol: executive summary.  The National Cholesterol Education Program Working Group on Lipoprotein Measurement. * Clin Chem* 1995; **41**: 1427--1433.7.National Heart Lung and Blood Institute.  Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. * Pediatrics* 2011; **128**(Suppl 5): S213--256.8.Hayward RA, Krumholz HM.  Three reasons to abandon low-density lipoprotein targets: an open letter to the Adult Treatment Panel IV of the National Institutes of Health. * Circ Cardiovasc Qual Outcomes* 2012; **5**: 2--5.9.Takahashi O, Glasziou PP, Perera R *et al.*  Lipid re-screening: what is the best measure and interval? * Heart* 2010; **96**: 448--452.10.Glasziou PP, Irwig L, Heritier S *et al.*  Monitoring cholesterol levels: measurement error or true change? * Ann Intern Med* 2008; **148**: 656--661.11.Jafri H, Karas RH, Alsheikh-Ali AA.  Meta-analysis: Statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. * Ann Intern Med* 2010; **153**: 800--808.12.Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). * JAMA* 2001; **285**: 2486--2497.13.Sandhu S, Wiebe N, Fried LF *et al.*  Statins for improving renal outcomes: a meta-analysis. * J Am Soc Nephrol* 2006; **17**: 2006--2016.14.Baigent C, Landray MJ, Reith C *et al.*  The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. * Lancet* 2011; **377**: 2181--2192.15.Lewington S, Whitlock G, Clarke R *et al.*  Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. * Lancet* 2007; **370**: 1829--1839.16.Chiang CK, Ho TI, Hsu SP *et al.*  Low-density lipoprotein cholesterol: association with mortality and hospitalization in hemodialysis patients. * Blood Purif* 2005; **23**: 134--140.17.Coresh J, Longenecker JC, Miller III ER *et al.*  Epidemiology of cardiovascular risk factors in chronic renal disease. * J Am Soc Nephrol* 1998; **9**: S24--S30.18.Iseki K, Yamazato M, Tozawa M *et al.*  Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. * Kidney Int* 2002; **61**: 1887--1893.19.Lowrie EG, Lew NL.  Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. * Am J Kidney Dis* 1990; **15**: 458--482.20.Krane V, Winkler K, Drechsler C *et al.*  Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus. * Am J Kidney Dis* 2009; **54**: 902--911.21.Liu Y, Coresh J, Eustace JA *et al.*  Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. * JAMA* 2004; **291**: 451--459.22.Tonelli M, Muntner P, Lloyd A *et al.*  Association between LDL-C and Risk of Myocardial Infarction in CKD. * J Am Soc Nephrol* 2013; **24**: 979--986.23.Grundy SM.  Diabetes and coronary risk equivalency: what does it mean? * Diabetes Care* 2006; **29**: 457--460.24.Cooper A, Nherera L, Calvert N *et al. Clinical Guidelines and Evidence Review for Lipid Modification: Cardiovascular Risk Assessment and the Primary and Secondary Prevention of Cardiovascular Disease.  Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease*.  National Collaborating Centre for Primary Care and Royal College of General Practitioners, London, 2008.25.Graham I, Atar D, Borch-Johnsen K *et al.*  European guidelines on cardiovascular disease prevention in clinical practice: full text.  Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). * Eur J Cardiovasc Prev Rehabil* 2007; **14**(Suppl 2): S1--113.26.Reiner Z, Catapano AL, De Backer G *et al.*  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). * Eur Heart J* 2011; **32**: 1769--1818.27.Tonelli M, Muntner P, Lloyd A *et al.*  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. * Lancet* 2012; **380**: 807--814.28.Herzog CA, Ma JZ, Collins AJ.  Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. * N Engl J Med* 1998; **339**: 799--805.29.Anavekar NS, McMurray JJ, Velazquez EJ *et al.*  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. * N Engl J Med* 2004; **351**: 1285--1295.30.Ezekowitz J, McAlister FA, Humphries KH *et al.*  The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. * J Am Coll Cardiol* 2004; **44**: 1587--1592.31.Latif F, Kleiman NS, Cohen DJ *et al.*  In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. * JACC Cardiovasc Interv* 2009; **2**: 37--45.32.Shepherd J, Kastelein JJ, Bittner V *et al.*  Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. * J Am Coll Cardiol* 2008; **51**: 1448--1454.33.Athyros VG, Tziomalos K, Gossios TD *et al.*  Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. * Lancet* 2010; **376**: 1916--1922.34.Palmer SC, Craig JC, Navaneethan SD *et al.*  Benefits and harms of statin therapy for persons With chronic kidney disease: A systematic review and meta-analysis. * Ann Intern Med* 2012; **157**: 263--275.35.Colhoun HM, Betteridge DJ, Durrington PN *et al.*  Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). * Am J Kidney Dis* 2009; **54**: 810--819.36.Tonelli M, Jose P, Curhan G *et al.*  Proteinuria, impaired kidney function, and adverse outcomes in people with coronary disease: analysis of a previously conducted randomised trial. * BMJ* 2006; **332**: 1426.37.Asselbergs FW, Diercks GF, Hillege HL *et al.*  Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. * Circulation* 2004; **110**: 2809--2816.38.Wilson PW, D\'Agostino RB, Levy D *et al.*  Prediction of coronary heart disease using risk factor categories. * Circulation* 1998; **97**: 1837--1847.39.Perk J, De Backer G, Gohlke H *et al.*  European Guidelines on cardiovascular disease prevention in clinical practice (version 2012).  The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). * Eur Heart J* 2012; **33**: 1635--1701.40.Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. * Circulation* 2002; **105**: 310--315.41.Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). * Heart* 2007; **93**: 172--176.42.Hippisley-Cox J, Coupland C, Vinogradova Y *et al.*  Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. * BMJ* 2008; **336**: 1475--1482.43.Wanner C, Krane V, Marz W *et al.*  Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. * N Engl J Med* 2005; **353**: 238--248.44.Fellstrom BC, Jardine AG, Schmieder RE *et al.*  Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. * N Engl J Med* 2009; **360**: 1395--1407.45.Upadhyay A, Earley A, Lamont JL *et al.*  Lipid-lowering therapy in persons With chronic kidney disease: A systematic Review and meta-analysis. * Ann Intern Med* 2012; **157**: 251--262.46.Hou W, Lv J, Perkovic V *et al.*  Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. * Eur Heart J* 2013; **34**: 1807--1817.47.Marz W, Genser B, Drechsler C *et al.*  Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. * Clin J Am Soc Nephrol* 2011; **6**: 1316--1325.48.Holdaas H, Fellstrom B, Jardine AG *et al.*  Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. * Lancet* 2003; **361**: 2024--2031.49.Pilmore H, Dent H, Chang S *et al.*  Reduction in cardiovascular death after kidney transplantation. * Transplantation* 2010; **89**: 851--857.50.Saito Y, Goto Y, Dane A *et al.*  Randomized dose-response study of rosuvastatin in Japanese patients with hypercholesterolemia. * J Atheroscler Thromb* 2003; **10**: 329--336.51.Saito Y, Goto Y, Nakaya N *et al.*  Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects.  A double blind test. * Atherosclerosis* 1988; **72**: 205--211.52.Nakamura H, Arakawa K, Itakura H *et al.*  Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. * Lancet* 2006; **368**: 1155--1163.53.Nakamura H, Mizuno K, Ohashi Y *et al.*  Pravastatin and cardiovascular risk in moderate chronic kidney disease. * Atherosclerosis* 2009; **206**: 512--517.54.Foley RN, Parfrey PS, Sarnak MJ.  Clinical epidemiology of cardiovascular disease in chronic renal disease. * Am J Kidney Dis* 1998; **32**: S112--119.55.Srinivasan SR, Myers L, Berenson GS.  Distribution and correlates of non-high-density lipoprotein cholesterol in children: the Bogalusa Heart Study. * Pediatrics* 2002; **110**: e29.56.Strong JP, Malcom GT, McMahan CA *et al.*  Prevalence and extent of atherosclerosis in adolescents and young adults: implications for prevention from the Pathobiological Determinants of Atherosclerosis in Youth Study. * JAMA* 1999; **281**: 727--735.57.Berenson GS, Srinivasan SR, Bao W *et al.*  Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults.  The Bogalusa Heart Study. * N Engl J Med* 1998; **338**: 1650--1656.58.Magnussen CG, Raitakari OT, Thomson R *et al.*  Utility of currently recommended pediatric dyslipidemia classifications in predicting dyslipidemia in adulthood: evidence from the Childhood Determinants of Adult Health (CDAH) study, Cardiovascular Risk in Young Finns Study, and Bogalusa Heart Study. * Circulation* 2008; **117**: 32--42.59.Schrott HG, Bucher KA, Clarke WR *et al.*  The Muscatine hyperlipidemia family study program. * Prog Clin Biol Res* 1979; **32**: 619--646.60.Jarvisalo MJ, Jartti L, Nanto-Salonen K *et al.*  Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. * Circulation* 2001; **104**: 2943--2947.61.Kavey RE, Allada V, Daniels SR *et al.*  Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics. * Circulation* 2006; **114**: 2710--2738.62.Olson RE.  Atherogenesis in children: implications for the prevention of atherosclerosis. * Adv Pediatr* 2000; **47**: 55--78.63.Saland JM, Ginsberg H, Fisher EA.  Dyslipidemia in pediatric renal disease: epidemiology, pathophysiology, and management. * Curr Opin Pediatr* 2002; **14**: 197--204.64.Saland JM, Ginsberg HN.  Lipoprotein metabolism in chronic renal insufficiency. * Pediatr Nephrol* 2007; **22**: 1095--1112.65.National Kidney Foundation.  KDOQI Clinical Practice Guideline for Nutrition in Children with CKD: 2008 update. * Am J Kidney Dis* 2009; **53**: S1--124.66.USRDS. * US Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States*.  Bethesda, MD, 2004.67.Kwiterovich PO Jr, Barton BA, McMahon RP *et al.*  Effects of diet and sexual maturation on low-density lipoprotein cholesterol during puberty: the Dietary Intervention Study in Children (DISC). * Circulation* 1997; **96**: 2526--2533.68.Niinikoski H, Koskinen P, Punnonen K *et al.*  Intake and indicators of iron and zinc status in children consuming diets low in saturated fat and cholesterol: the STRIP baby study.  Special Turku Coronary Risk Factor Intervention Project for Babies. * Am J Clin Nutr.*  1997; **66**: 569--574.69.Niinikoski H, Lapinleimu H, Viikari J *et al.*  Growth until 3 years of age in a prospective, randomized trial of a diet with reduced saturated fat and cholesterol. * Pediatrics* 1997; **99**: 687--694.70.Niinikoski H, Viikari J, Ronnemaa T *et al.*  Regulation of growth of 7- to 36-month-old children by energy and fat intake in the prospective, randomized STRIP baby trial. * Pediatrics* 1997; **100**: 810--816.71.Coleman JE, Watson AR.  Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. * Pediatr Nephrol* 1996; **10**: 171--174.72.Garcia-de-la-Puente S, Arredondo-Garcia JL, Gutierrez-Castrellon P *et al.*  Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders. * Pediatr Nephrol* 2009; **24**: 1205--1210.73.Sanjad SA, al-Abbad A, al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. * J Pediatr* 1997; **130**: 470--474.74.Yoshimura N, Oka T, Okamoto M *et al.*  The effects of pravastatin on hyperlipidemia in renal transplant recipients. * Transplantation* 1992; **53**: 94--99.75.Avis HJ, Hutten BA, Gagne C *et al.*  Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. * J Am Coll Cardiol* 2010; **55**: 1121--1126.76.Clauss SB, Holmes KW, Hopkins P *et al.*  Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. * Pediatrics* 2005; **116**: 682--688.77.de Jongh S, Lilien MR, op\'t Roodt J *et al.*  Early statin therapy restores endothelial function in children with familial hypercholesterolemia. * J Am Coll Cardiol* 2002; **40**: 2117--2121.78.de Jongh S, Ose L, Szamosi T *et al.*  Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. * Circulation* 2002; **106**: 2231--2237.79.Knipscheer HC, Boelen CC, Kastelein JJ *et al.*  Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. * Pediatr Res* 1996; **39**: 867--871.80.Lambert M, Lupien PJ, Gagne C *et al.*  Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin.  Canadian Lovastatin in Children Study Group. * Pediatrics* 1996; **97**: 619--628.81.McCrindle BW, Helden E, Cullen-Dean G *et al.*  A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. * Pediatr Res* 2002; **51**: 715--721.82.McCrindle BW, Ose L, Marais AD.  Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. * J Pediatr* 2003; **143**: 74--80.83.Rodenburg J, Vissers MN, Wiegman A *et al.*  Statin treatment in children with familial hypercholesterolemia: the younger, the better. * Circulation* 2007; **116**: 664--668.84.Stein EA, Illingworth DR, Kwiterovich PO Jr *et al.*  Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. * JAMA* 1999; **281**: 137--144.85.van der Graaf A, Cuffie-Jackson C, Vissers MN *et al.*  Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. * J Am Coll Cardiol* 2008; **52**: 1421--1429.86.van der Graaf A, Nierman MC, Firth JC *et al.*  Efficacy and safety of fluvastatin in children and adolescents with heterozygous familial hypercholesterolaemia. * Acta Paediatr* 2006; **95**: 1461--1466.87.Wiegman A, Hutten BA, de Groot E *et al.*  Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. * JAMA* 2004; **292**: 331--337.88.Preiss D, Tikkanen MJ, Welsh P *et al.*  Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. * JAMA* 2012; **308**: 804--811.89.Baigent C, Blackwell L, Emberson J *et al.*  Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. * Lancet* 2010; **376**: 1670--1681.90.Jun M, Foote C, Lv J *et al.*  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. * Lancet* 2010; **375**: 1875--1884.91.Tonelli M, Collins D, Robins S *et al.*  Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. * Kidney Int* 2004; **66**: 1123--1130.92.Ansquer JC, Foucher C, Rattier S *et al.*  Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). * Am J Kidney Dis* 2005; **45**: 485--493.93.Keech A, Simes RJ, Barter P *et al.*  Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. * Lancet* 2005; **366**: 1849--1861.94.Ting RD, Keech AC, Drury PL *et al.*  Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study. * Diabetes Care* 2012; **35**: 218--225.95.Davis TM, Ting R, Best JD *et al.*  Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. * Diabetologia* 2011; **54**: 280--290.96.Ginsberg HN, Elam MB, Lovato LC *et al.*  Effects of combination lipid therapy in type 2 diabetes mellitus. * N Engl J Med* 2010; **362**: 1563--1574.97.Zhao YY, Weir MA, Manno M *et al.*  New fibrate use and acute renal outcomes in elderly adults a population-based study. * Ann Intern Med* 2012; **156**: 560--569.98.Chen HH, Lin LH.  Recurrent pancreatitis secondary to type V hyperlipidemia: report of one case. * Acta Paediatr Taiwan* 2000; **41**: 276--278.99.Spratt P, Esmore D, Keogh A *et al.*  Comparison of three immunosuppressive protocols in cardiac transplantation. * Transplant Proc* 1989; **21**: 2481--2483.100.Chicaud P, Demange J, Drouin P *et al.*  \[Action of fenofibrate in hypercholesterolemic children.  18-month follow-up\]. * Presse Med* 1984; **13**: 417--419.101.Steinmetz J, Morin C, Panek E *et al.*  Biological variations in hyperlipidemic children and adolescents treated with fenofibrate. * Clin Chim Acta* 1981; **112**: 43--53.102.Wheeler KA, West RJ, Lloyd JK *et al.*  Double blind trial of bezafibrate in familial hypercholesterolaemia. * Arch Dis Child* 1985; **60**: 34--37.103.Cerkauskiene R, Kaminskas A, Kaltenis P *et al.*  Influence of omega-3 fatty acids on lipid metabolism in children with steroid sensitive nephrotic syndrome\]. * Medicina* 2003; **39**(Suppl 1): 82-87.104.Chongviriyaphan N, Tapaneya-Olarn C, Suthutvoravut U *et al.*  Effects of tuna fish oil on hyperlipidemia and proteinuria in childhood nephrotic syndrome. * J Med Assoc Thai* 1999; **82**(Suppl 1): S122--S128.105.Goren A, Stankiewicz H, Goldstein R *et al.*  Fish oil treatment of hyperlipidemia in children and adolescents receiving renal replacement therapy. * Pediatrics* 1991; **88**: 265--268.106.Hogg RJ, Lee J, Nardelli N *et al.*  Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. * Clin J Am Soc Nephrol* 2006; **1**: 467--474.107.Owens DK, Lohr KN, Atkins D *et al.*  AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions\--agency for healthcare research and quality and the effective health-care program. * J Clin Epidemiol* 2010; **63**: 513--523.108.Atkins D, Best D, Briss PA *et al.*  Grading quality of evidence and strength of recommendations. * BMJ* 2004; **328**: 1490.109.Guyatt GH, Oxman AD, Kunz R *et al.*  Going from evidence to recommendations. * BMJ* 2008; **336**: 1049--1051.110.Uhlig K, Macleod A, Craig J *et al.*  Grading evidence and recommendations for clinical practice guidelines in nephrology.  A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). * Kidney Int* 2006; **70**: 2058--2065.111.The AGREE Collaboration.  Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: the AGREE project. * Qual Saf Health Care* 2003; **12**: 18--23.112.Shiffman RN, Shekelle P, Overhage JM *et al.*  Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization. * Ann Intern Med* 2003; **139**: 493--498.113.Institute of Medicine. * Finding What Works in Health Care: Standards for Systematic Reviews*.  The National Academies Press: Washington, DC, 2011.114.Institute of Medicine. * Clinical Practice Guidelines We Can Trust*.  National Academies Press: Washington, DC, 2011.